Alpine Immune Sciences, Inc. (ALPN) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Seattle, WA, United States. वर्तमान CEO हैं Mitchell H. Gold.
ALPN के पास है IPO तिथि 2015-06-17, 142 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $4.46B.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer, autoimmune disorders, and inflammatory diseases. The company's pipeline includes ALPN-101, an ICOS/CD28 antagonist for autoimmune and inflammatory conditions; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for cancer treatment; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated diseases. Alpine has established strategic collaborations with AbbVie Ireland for ALPN-101 development and with Adaptimmune Therapeutics for next-generation SPEAR T cell products. Founded in 2007 and headquartered in Seattle, Washington, the company leverages its immunotherapy expertise to address significant unmet medical needs across multiple therapeutic areas.
